IMDELLTRA (AMG757)
Biological
Amgen Inc.
Total Payments
$37.6M
Transactions
340
Doctors
8
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $37.6M | 340 | 8 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $37.6M | 340 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer | Amgen Inc. | $14.2M | 0 |
| Tarlatamab 20200469 | Amgen Inc. | $8.7M | 0 |
| P3 2L SCLC 2-Arm Mono 757 vs SOC . | Amgen Inc. | $4.5M | 0 |
| P3 LS-SCLC Mono 757 vs Placebo | Amgen Inc. | $2.8M | 1 |
| P3 3L+ SCLC Mono Exp Access . | Amgen Inc. | $2.5M | 0 |
| P3 1L SCLC Maintenance | Amgen Inc. | $1.7M | 0 |
| Tarlatamab 20200439 | Amgen Inc. | $821,489 | 0 |
| Expanded Access Request for Tarlatamab to treat a 58 y.o. female for chemotherapy refractory metastatic extrapulmonary high grade small cell neuroendocrine cancer of the breast | Amgen Inc. | $544,001 | 0 |
| Ph1_Tarlatamab_Sub-Q | Amgen Inc. | $407,855 | 0 |
| Evaluation of target expression and T cell redirecting antibody activity in prostate cancer | Amgen Inc. | $183,582 | 0 |
| Expanded Access Request for Tarlatamab to treat a 56 y.o. female Patient for Refractory Extensive Stage Small Cell Lung Cancer SCLC | Amgen Inc. | $181,834 | 0 |
| Expanded Access Request for Tarlatamab to treat a Patient with Small Cell Lung Cancer SCLC | Amgen Inc. | $181,834 | 0 |
| Expanded Access request for Tarlatamab to treat a 39 y.o. male for Small Cell Lung Cancer SCLC | Amgen Inc. | $181,834 | 0 |
| Expanded Access Request for Tarlatamab to treat a 77 yo male patient with DLL3+ Extrapulmonary small cell carcinoma neuroendocrine small cell prostate cancer. | Amgen Inc. | $181,722 | 0 |
| P2 3L+ Registration Exp SCLC. | Amgen Inc. | $160,975 | 1 |
| Tarlatamab Ph1b/2 R/R NEPC. | Amgen Inc. | $130,888 | 0 |
| Tarlatamab EA Request for the Treatment of an 18 yo male with SCLC | Amgen Inc. | $91,722 | 0 |
| Expanded Access Request for Tarlatamab to treat Patient CS with Small Cell Lung Cancer SCLC | Amgen Inc. | $91,611 | 0 |
| Evaluation of AMG 757 in preclinical models of SCLC | Amgen Inc. | $48,600 | 0 |
| P1b 2L+ Tarlatamab + ADC | Amgen Inc. | $15,000 | 0 |
Top Doctors Receiving Payments for IMDELLTRA (AMG757)
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Pikeville, KY | $37.6M | 332 |
| , M.D | Specialist | Philadelphia, PA | $4,467 | 1 |
| , MD | Medical Oncology | Atlanta, GA | $4,467 | 1 |
| , M.D | Diagnostic Radiology | Philadelphia, PA | $4,010 | 1 |
| , FNP-BC, APRN | Family | Boston, MA | $2,579 | 1 |
| , M.D | Internal Medicine | Boston, MA | $500.00 | 1 |
| , M.D., PH.D | Internal Medicine | Houston, TX | $24.15 | 1 |
| , MD | Internal Medicine | Boston, MA | $24.15 | 1 |
| , MD | Student in an Organized Health Care Education/Training Program | Durham, NC | $24.15 | 1 |
Ad
Manufacturing Companies
- Amgen Inc. $37.6M
Product Information
- Type Biological
- Total Payments $37.6M
- Total Doctors 8
- Transactions 340
About IMDELLTRA (AMG757)
IMDELLTRA (AMG757) is a biological associated with $37.6M in payments to 8 healthcare providers, recorded across 340 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2024 to 2024. In 2024, $37.6M was paid across 340 transactions to 8 doctors.
The most common payment nature for IMDELLTRA (AMG757) is "Unspecified" ($37.6M, 100.0% of total).
IMDELLTRA (AMG757) is associated with 20 research studies, including "A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer" ($14.2M).